GSK
GSK
787 hedge funds and large institutions have $11.1B invested in GSK in 2018 Q2 according to their latest regulatory filings, with 66 funds opening new positions, 223 increasing their positions, 309 reducing their positions, and 51 closing their positions.
80% more call options, than puts
Call options by funds: $145M | Put options by funds: $80.5M
29% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 51
1% more funds holding
Funds holding: 779 → 787 (+8)
0.07% less ownership
Funds ownership: 10.97% → 10.89% (-0.07%)
7% less funds holding in top 10
Funds holding in top 10: 15 → 14 (-1)
11% less capital inflows, than outflows
Capital inflows: $489M | Capital outflows: $552M
28% less repeat investments, than reductions
Existing positions increased: 223 | Existing positions reduced: 309
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$73.1M |
| 2 |
Jane Street
New York
|
+$60.2M |
| 3 |
Renaissance Technologies
New York
|
+$49M |
| 4 |
Eaton Vance Management
Boston,
Massachusetts
|
+$48.7M |
| 5 |
Morgan Stanley
New York
|
+$23.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Camber Capital Management
Boston,
Massachusetts
|
-$58.6M |
| 2 |
Two Sigma Advisers
New York
|
-$51M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$36.8M |
| 4 |
Deerfield Management
New York
|
-$31.6M |
| 5 |
Old Republic International (ORI)
Chicago,
Illinois
|
-$28.9M |
GSK Hedge Fund Activity: Q2 2018 in Review
787 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q2 2018, worth a combined $11.1B — up 2.5% from $10.8B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new GSK positions and 51 closed out — a net gain of 15 holders — while 223 added to existing stakes and 309 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $73.1M. The largest seller was Camber Capital Management, exiting entirely with an estimated $58.6M sold.
- 787 institutional investors held GSK (GSK) as of Q2 2018, up from 779 in Q1 2018.
- Funds reported $11.1B of GSK stock for Q2 2018, up 2.5% quarter-over-quarter.
- 66 funds opened new GSK positions in Q2 2018 and 51 closed out, a net change of +15 holders.
- The largest GSK buyer in Q2 2018 was Deutsche Bank, an estimated $73.1M added.
- The largest GSK seller in Q2 2018 was Camber Capital Management, an estimated $58.6M sold.
Based on aggregated 13F filings for Q2 2018.